PL3193917T3 - Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty - Google Patents

Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty

Info

Publication number
PL3193917T3
PL3193917T3 PL15774851T PL15774851T PL3193917T3 PL 3193917 T3 PL3193917 T3 PL 3193917T3 PL 15774851 T PL15774851 T PL 15774851T PL 15774851 T PL15774851 T PL 15774851T PL 3193917 T3 PL3193917 T3 PL 3193917T3
Authority
PL
Poland
Prior art keywords
dioxygenase
tryptophan
fragments
vaccine compositions
vaccine
Prior art date
Application number
PL15774851T
Other languages
English (en)
Polish (pl)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of PL3193917T3 publication Critical patent/PL3193917T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/11—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of two atoms of oxygen (1.13.11)
    • C12Y113/11011—Tryptophan 2,3-dioxygenase (1.13.11.11), i.e. indolamine 2,3-dioxygenase 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Rehabilitation Therapy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
PL15774851T 2014-09-17 2015-09-15 Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty PL3193917T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470571 2014-09-17
PCT/DK2015/050274 WO2016041560A1 (en) 2014-09-17 2015-09-15 Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
EP15774851.8A EP3193917B9 (en) 2014-09-17 2015-09-15 Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

Publications (1)

Publication Number Publication Date
PL3193917T3 true PL3193917T3 (pl) 2022-01-17

Family

ID=51661826

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15774851T PL3193917T3 (pl) 2014-09-17 2015-09-15 Kompozycje szczepionek zawierające 2,3-dioksygenazę tryptofanową lub jej fragmenty

Country Status (18)

Country Link
US (2) US10736950B2 (enExample)
EP (2) EP3193917B9 (enExample)
JP (1) JP6811710B2 (enExample)
CN (1) CN106999557B (enExample)
AU (1) AU2015317446B2 (enExample)
CA (1) CA2959197C (enExample)
CY (1) CY1124738T1 (enExample)
DK (1) DK3193917T3 (enExample)
ES (1) ES2891902T3 (enExample)
HR (1) HRP20211540T2 (enExample)
HU (1) HUE056414T2 (enExample)
IL (1) IL251101B (enExample)
LT (1) LT3193917T (enExample)
PL (1) PL3193917T3 (enExample)
PT (1) PT3193917T (enExample)
SI (1) SI3193917T1 (enExample)
WO (1) WO2016041560A1 (enExample)
ZA (1) ZA201701179B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110628736B (zh) * 2019-10-09 2021-05-11 扬州大学 色氨酸2,3双加氧酶突变体及其制备方法和应用
CN111012919B (zh) * 2019-12-23 2021-06-01 山东大学 聚乙二醇化的icd诱导剂-ido抑制剂纳米缀合物及制备方法与应用
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
EP4340948A4 (en) * 2021-05-17 2025-03-12 Wisconsin Alumni Research Foundation (WARF) SYNTHETIC PROTEIN TO INDUCE IMMUNE TOLERANCE
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
EP1522594A3 (en) * 2003-10-06 2005-06-22 Bayer HealthCare AG Methods and kits for investigating cancer
DE102004039196B4 (de) * 2004-08-12 2008-07-31 Dr.Kamprad Kg Neue Formulierung für L-Tryptophan
US20110159017A1 (en) * 2008-04-11 2011-06-30 Ludwig Institute For Cancer Research Ltd. Trytophan catabolism in cancer treatment and diagnosis
US9433666B2 (en) * 2008-04-17 2016-09-06 IO Bioech ApS Indoleamine 2,3-dioxygenase based immunotherapy
CA3197245A1 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
CA2850245C (en) 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
GB201120860D0 (en) * 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy

Also Published As

Publication number Publication date
LT3193917T (lt) 2021-11-25
ES2891902T9 (es) 2022-03-02
ZA201701179B (en) 2021-05-26
EP3919074A1 (en) 2021-12-08
US11878053B2 (en) 2024-01-23
EP3193917B1 (en) 2021-08-18
HRP20211540T2 (hr) 2022-05-13
EP3193917A1 (en) 2017-07-26
IL251101A0 (en) 2017-04-30
ES2891902T3 (es) 2022-01-31
CN106999557A (zh) 2017-08-01
IL251101B (en) 2021-05-31
EP3193917B9 (en) 2022-02-16
CN106999557B (zh) 2021-04-20
SI3193917T1 (sl) 2022-02-28
JP6811710B2 (ja) 2021-01-20
CA2959197A1 (en) 2016-03-24
JP2017533182A (ja) 2017-11-09
HUE056414T2 (hu) 2022-02-28
PT3193917T (pt) 2021-10-20
AU2015317446A1 (en) 2017-04-20
DK3193917T3 (da) 2021-10-04
US10736950B2 (en) 2020-08-11
US20210023191A1 (en) 2021-01-28
HRP20211540T1 (hr) 2021-12-24
WO2016041560A1 (en) 2016-03-24
NZ730708A (en) 2024-01-26
CY1124738T1 (el) 2022-07-22
CA2959197C (en) 2023-03-14
AU2015317446B2 (en) 2020-08-13
US20170239337A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
ZA201801035B (en) Vaccine compositions
IL254124A0 (en) New 3-indole-transformed histories, medicinal preparations and methods of use
GB201610599D0 (en) Immunogenic Composition
IL248223B (en) Compositions of vaccine
ZA201608487B (en) Dual adjuvant vaccine compositions, preparation and uses
SG11201701256RA (en) Vaccine compositions against dengue virus diseases
EP3131579A4 (en) Vaccine adjuvant compositions
ZA201702086B (en) Long acting pharmaceutical compositions
HUE056175T2 (hu) Gyógyászati készítmények, elõállításuk és alkalmazásaik
IL251101B (en) Vaccine compounds comprising tryptophan 3,2-dioxygenase or fragments thereof
EP3397277C0 (en) IMMUNOGENIC COMPOSITION
IL248256B (en) Cyclohexenyl compounds, compositions comprising them and uses thereof
PT3157912T (pt) Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
IL252683A0 (en) Pyridyl-cycloalkyl-substituted carboxylic acids, preparations containing them and their medical uses
PL3166572T3 (pl) Kompozycje do higieny jamy ustnej zwalczające kamień nazębny
GB2562241B (en) Vaccine compositions
GB201614485D0 (en) Immunogenic composition
GB201703529D0 (en) Vaccine composition
GB2509426B (en) Clomazone composition, its preparation and use thereof
GB201718251D0 (en) Vaccine Compositions
GB2564901B (en) Vaccine compositions
GB201611084D0 (en) Vaccine compositions
GB201521608D0 (en) Vaccine composition
GB201401883D0 (en) Combination immunogenic compositions
GB201411371D0 (en) Immunogenic composition